News

Carina Biotech appoints Cell Therapies to undertake manufacture of LGR5 CAR-T cells for clinical trial

2022-05-31T11:04:59+09:30May 31st, 2022|News, Uncategorised|

Carina Biotech is pleased to announce that it has appointed Australian organisation Cell Therapies to undertake Good Manufacturing Processes (GMP) manufacture of its LGR5 CAR-T cells for a first-in-human clinical

Carina Biotech Symposium 2022 Program

2022-05-17T12:04:11+09:30May 17th, 2022|News|

Carina Biotech Symposium Program Wednesday, 18 May 2022 Hotel Grand Chancellor Adelaide + online Join from a PC, Mac, iOS or Android: https://unisa.zoom.us/j/86263467920?pwd=WXNCZCtTYkw4RTIyTUdNREpjbjlqZz09 Password: 720700    9:30 am – 10

Carina Biotech inaugural symposium to be held on 18 May 2022 in Adelaide and virtually

2022-04-14T10:31:03+09:30April 14th, 2022|News|

PLEASE JOIN US on Wednesday, 18 May 2022 9:30 am – 5:00 pm for Carina Biotech's inaugural symposium Join us in Adelaide at the Hotel Grand Chancellor and virtually for Carina

Carina Biotech to showcase its LGR5 CAR-T program at the American Association for Cancer Research (AACR) Annual Meeting

2022-04-06T10:18:54+09:30April 6th, 2022|News|

Carina has had five abstracts accepted for poster presentations at the AACR Annual Meeting which will take place from April 8 to April 13. The poster presentations come after Carina’s

Carina Biotech submits LGR5 CAR-T pre-IND (Investigational New Drug) package to the US Food & Drug Administration

2022-04-01T08:39:54+09:30April 1st, 2022|News, Uncategorised|

Carina Biotech is very pleased to announce that we have submitted a pre-IND (Investigational New Drug) application to the US FDA (Food & Drug Administration) for our CAR-T therapy that targets a

Carina Biotech licenses German technology to create highly efficient CAR-T cells targeting hard-to-treat cancers

2021-12-15T08:38:03+09:30December 15th, 2021|News, Uncategorised|

Carina Biotech has entered a license agreement with Bayerische Patentallianz (BayPAT) to the CXCR6-transduced CAR-T cell technology developed at the University Hospital of Ludwig-Maximillian University of Munich (LMU). The agreement

Manufacture of Carina’s LGR5 CAR-T has begun with CellVec contracted to produce GMP-grade lentivirus constructs

2021-11-09T11:02:58+09:30November 9th, 2021|News|

Singapore-based CellVec will manufacture clinical-grade lentivirus – the first critical step in making LGR5 CAR-T cells for a first-in-human clinical trial for patients with advanced colorectal (bowel) cancer in late